Shanghai-based OTR Therapeutics and South Korea-based LG Chem (KRX: 051910) have announced a multi-program strategic collaboration to identify, evaluate, and advance oncology assets sourced from China’s biopharma ecosystem into global development. The agreement gives LG Chem a systematic channel for accessing early-stage Chinese oncology programs at a point when asset valuations are lower and clinical risk has not yet been priced in, while providing OTR with a large-pharma partner to fund and execute ex-China development and commercialization. No specific programs have been identified under the framework, and no aggregate deal value was disclosed.
Under the collaboration structure, OTR will screen oncology candidates using its Shanghai-based R&D platform and regional scientific network, conduct initial technical assessments, and lead preclinical and early clinical development. LG Chem will assume responsibility for ex-China clinical development, regulatory strategy, and commercialization. Individual program-specific agreements will govern each asset advanced through the framework. OTR will receive upfront payments and development and regulatory milestone payments under each such agreement. OTR also retains an option to co-participate in global development and obtain a share of global rights for programs that enter late-stage clinical development, a provision that could convert the arrangement from a straight licensing model into a co-development structure for the most advanced assets.
LG Chem has been building its oncology pipeline through a combination of acquisitions, internal development, and external licensing across multiple modalities. The company acquired AVEO Oncology in January 2023, gaining its first US FDA-approved oncology asset, tivozanib (Fotivda), and has since advanced AVEO’s ficlatuzumab into a Phase III registrational trial in HPV-negative recurrent or metastatic head and neck squamous cell carcinoma. In April 2026, LG Chem licensed FMC-220, a covalent p53 Y220C activator, from Frontier Medicines for ex-Greater China development, and in June 2026 entered a research collaboration and option agreement with UK-based LabGenius Therapeutics for an AI-designed multispecific antibody targeting solid tumors. The OTR collaboration extends this pattern by adding a standing pipeline-sourcing mechanism rather than a single-asset deal.
OTR, launched in March 2025, demonstrated the same operating model in December 2025 when it entered a multi-program collaboration with Zealand Pharma (Nasdaq: ZEAL) to discover and develop oral small-molecule metabolic disease therapies from its China R&D hub, receiving an initial upfront payment of USD 20 million, potentially rising to USD 30 million, and eligibility for up to approximately USD 2.5 billion in total consideration including tiered royalties.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/